Facial Reanimation Surgery in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Adults and children (typically ≥5 years) with unilateral or bilateral facial paralysis of any etiology, including Bell's palsy with incomplete recovery, acoustic neuroma or skull base tumour resection, parotid gland surgery, temporal bone fracture, Möbius syndrome, hemifacial microsomia, or congenital facial palsy

• Patients with House-Brackmann Grade III–VI paralysis persisting beyond 6 months despite conservative management

• Patients with intact ipsilateral distal facial nerve branches (suitable for direct nerve repair or nerve graft) or those requiring donor nerve sources (great auricular nerve, sural nerve, CFNG)

• Patients with paralysis duration under 18–24 months who retain viable mimetic muscle (confirmed by EMG showing fibrillation potentials or nascent motor unit potentials)

• Patients with paralysis exceeding 24 months and complete muscle fibrofatty replacement who are candidates for free functional muscle transfer (gracilis FFMT powered by CFNG or masseteric nerve)

• Patients with lagophthalmos (corneal exposure risk) requiring urgent upper lid loading (gold or platinum weight implantation) or lateral tarsorrhaphy regardless of overall reanimation timing

• Patients with synkinesis following aberrant facial nerve regeneration, suitable for chemodenervation (botulinum toxin) and neuromuscular retraining

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• High-resolution MRI of the facial nerve (1.5T or 3T with gadolinium enhancement; axial and coronal CISS/FIESTA sequences through the temporal bone)

• Electromyography (EMG) and electroneuronography (ENoG) of all five facial nerve branches

• Ophthalmologic assessment: Schirmer's test, corneal sensitivity, Bell's phenomenon, lagophthalmos measurement in mm

• Audiometry (if temporal bone or skull base pathology is involved)

• CT temporal bone (for fracture, cholesteatoma, or bony canal involvement)

• Complete blood count, coagulation profile (PT/INR/aPTT), HbA1c, renal and hepatic function panel

• Cardiopulmonary clearance (ECG, chest X-ray, echocardiography if indicated) for general anaesthesia fitness

• Nutritional assessment and albumin/pre-albumin levels (critical for free flap healing)

• Psychological assessment and counselling (validated depression/anxiety screening: PHQ-9, GAD-7)

• CONTRAINDICATIONS:

• Absolute: Active untreated malignancy at the surgical site; uncontrolled systemic coagulopathy; severe cardiopulmonary disease precluding general anaesthesia (ASA Class IV–V)

• Relative: Uncontrolled diabetes mellitus (HbA1c >9%); active smoking (significantly impairs free flap survival; mandatory cessation ≥4 weeks pre-operatively); severe peripheral vascular disease; prior extensive radiation to the operative field (increases flap failure risk); patient unwilling to comply with post-operative neuromuscular rehabilitation protocol

STATIC PROCEDURES (Immediate symmetry at rest; no volitional movement restored):

• Gold or platinum eyelid weight implantation: A 0.8–1.6 g implant is placed in the pre-tarsal space of the upper eyelid under local anaesthesia to correct lagophthalmos and protect the cornea. Platinum chains offer superior biocompatibility and MRI compatibility.

• Fascia lata static sling: Autologous fascia lata harvested from the thigh is woven through the face to suspend the oral commissure, nasal ala, and lower lid in a symmetrical position. Provides durable static support but no dynamic movement.

• Lower lid ectropion correction: Lateral tarsal strip procedure or canthoplasty to address paralytic ectropion and epiphora.

• Selective myectomy and brow lift: Address contralateral hyperkinesis or brow asymmetry.

DYNAMIC NERVE-BASED PROCEDURES (Restore volitional movement; best results when viable mimetic muscle remains):

• Primary facial nerve repair (neurorrhaphy): Gold standard when nerve ends are available within 72 hours of injury. Epineural repair under microscopic magnification using 9-0 or 10-0 nylon suture; tension-free anastomosis is mandatory.

• Interpositional nerve grafting: When a nerve gap exists (post-tumour resection), sural nerve or great auricular nerve graft bridges the defect. Outcomes correlate with graft length (<5 cm preferred) and patient age (<50 years optimal).

• Cross-face nerve grafting (CFNG): A sural nerve graft is tunnelled subcutaneously across the philtrum, with the proximal end coapted to a buccal branch of the contralateral (normal) facial nerve and the distal end staged for connection to either a direct nerve repair or as the motor input for a subsequent free muscle transfer. Provides spontaneous, emotionally driven smile. Typically performed as a two-stage procedure with a 9–12 month interval between stages.

• Hypoglossal-to-facial nerve transfer (XII-VII transfer): Provides strong and reliable reinnervation by rerouting the hypoglossal nerve (or a partial branch using an interposition jump graft to minimize tongue weakness) to the main facial nerve trunk. Modern technique uses a 30% partial hypoglossal nerve harvest to preserve tongue function. Results in a non-spontaneous, voluntary smile (requires conscious tongue activation initially, with cortical adaptation over time).

• Masseteric nerve (CN V3) to facial nerve transfer: The motor branch of the masseter muscle (a branch of the trigeminal nerve) is coapted to the buccal branch of the facial nerve. Provides powerful, reliable reinnervation with cortical adaptation leading to a near-spontaneous smile in many patients. Increasingly favoured as a single-stage procedure or in combination with CFNG (the 'babysitter' technique).

FREE FUNCTIONAL MUSCLE TRANSFER (FFMT) — For Long-Standing Paralysis (>18–24 months) or Muscle Absence:

• Gracilis FFMT (workhorse procedure): A segment of the gracilis muscle, with its obturator nerve and medial circumflex femoral artery/vein, is harvested from the medial thigh and inset into the face. The obturator nerve is coapted to either the CFNG (for spontaneous smile) or the masseteric nerve (for strong, fast movement). Microvascular anastomosis of artery and vein to recipient vessels (typically facial artery/vein or superficial temporal vessels). Reinnervation takes 6–12 months; smile excursion typically 10–16 mm.

• Latissimus dorsi FFMT: Used when a larger muscle volume is required (e.g., extensive tissue loss, bilateral paralysis, paediatric cases with Möbius syndrome).

• Segmental pectoralis minor FFMT: An alternative free muscle with consistent neurovascular anatomy.

ADJUNCTIVE AND EMERGING TECHNOLOGIES:

• Intraoperative facial nerve monitoring (continuous EMG): Mandatory during skull base and parotid surgery to identify and preserve facial nerve branches.

• Intraoperative nerve stimulation and mapping: Aids identification of distal nerve stumps.

• Fluorescence angiography (SPY system, ICG): Real-time assessment of free flap perfusion intraoperatively.

• Botulinum toxin type A (onabotulinumtoxinA / Botox): Injected into synkinetic muscle groups and into the contralateral hyperkinetic muscles to achieve dynamic symmetry. Typically 20–50 units per session, repeated every 3–4 months.

• Neuromuscular retraining (NMR) with EMG biofeedback: Specialized physiotherapy protocol to reduce synkinesis, improve selective muscle activation, and optimize cortical remapping. High-definition surface EMG devices allow real-time visual feedback.

• Platelet-Rich Plasma (PRP) nerve wrap: Investigational adjunct to enhance nerve regeneration at coaptation sites.

• Artificial intelligence-based eFACE digital measurement: Standardized, reproducible quantification of facial movement outcomes using video analysis, increasingly used in high-volume centres for outcome benchmarking.

PHASE 1 — PRE-TRAVEL & VIRTUAL CONSULTATION (4–8 weeks before travel):

• Patient submits medical records, photographs (standardized frontal and lateral at rest, maximum smile, eye closure, brow raise), and EMG/MRI reports to GAF Healthcare's clinical coordination team.

• A GAF-affiliated craniofacial or plastic surgeon reviews the case and provides a written surgical opinion, recommended procedure(s), and indicative cost estimate within 48–72 hours.

• Virtual video consultation with the surgeon to discuss surgical goals, realistic expectations, and recovery timeline.

• GAF Healthcare initiates e-Medical Visa application (India) or confirms UAE entry requirements. Travel and accommodation are arranged for the patient and one accompanying attendant.

PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Days 1–3):

• Airport transfer to hospital-affiliated accommodation or directly to the hospital.

• Day 1: Registration, clinical photography (standardized eFACE protocol), and consultation with the primary surgeon and the multidisciplinary team (ophthalmologist, speech-language pathologist, neurophysiologist, anaesthesiologist).

• Day 2: Completion of all pre-operative diagnostics (EMG, MRI review, ophthalmology, blood work, anaesthetic assessment). Surgical plan finalized and consented.

• Day 3 (or when medically cleared): Pre-operative preparation — bowel prep if indicated, chlorhexidine skin wash, cessation of anticoagulants/NSAIDs, DVT prophylaxis initiation (low-molecular-weight heparin).

PHASE 3 — SURGERY (Day 3 or 4; duration 4–14 hours depending on procedure):

• Static procedures (lid weight, sling): 1–3 hours under general or deep sedation anaesthesia.

• Nerve repair or grafting: 3–6 hours under general anaesthesia with intraoperative nerve monitoring.

• CFNG (Stage 1): 2–3 hours.

• Hypoglossal or masseteric nerve transfer: 3–5 hours.

• Gracilis FFMT: 8–14 hours (two simultaneous surgical teams — one for facial preparation and recipient vessel dissection, one for gracilis harvest).

• Intraoperative ICG fluorescence angiography performed to confirm flap perfusion before wound closure.

• Patient transferred to ICU or high-dependency unit (HDU) post-operatively for monitoring.

PHASE 4 — INPATIENT RECOVERY (Days 4–10):

• Free flap patients: Hourly flap monitoring for the first 48 hours (Doppler probe, clinical observation for colour, capillary refill, turgor). Strict head positioning maintained. IV antibiotics (cephalosporin + metronidazole), anticoagulation (aspirin 75 mg, low-dose heparin infusion per protocol), analgesia (multimodal: paracetamol, tramadol, regional nerve blocks where applicable).

• Nerve repair/graft patients: Pressure dressings, wound care, oral antibiotics, and analgesics. Earlier mobilization.

• Ophthalmology review on Day 2 post-op if eyelid surgery performed; moisture chamber or taping at night for lagophthalmos.

• Drain removal typically Day 2–4. Suture removal Day 7–10. Dietary progression from liquids to soft diet.

• Discharge from hospital: Day 3–5 for nerve procedures; Day 5–7 for FFMT.

PHASE 5 — OUTPATIENT RECOVERY IN COUNTRY (Weeks 2–6):

• Weeks 1–2 post-discharge: Daily wound review at outpatient clinic or by GAF-coordinated home nursing. Facial oedema and bruising peak at Days 3–5 and resolve progressively over 3–4 weeks.

• Weeks 2–4: Introduction of gentle facial exercises and neuromuscular retraining by the physiotherapist. Patients are advised to avoid strenuous activity, direct sun exposure, and contact sports.

• Week 3–4: Surgical review and clearance assessment. Wound photographs sent to surgeon. Sutures fully removed.

• Fit-to-fly assessment: Minimum 3 weeks for nerve procedures; minimum 4–6 weeks for gracilis FFMT (to ensure flap viability is stable and DVT risk is acceptable for long-haul flight).

• Pre-departure: GAF provides a discharge summary, operative report, post-operative instructions, and a letter for airline medical clearance.

PHASE 6 — LONG-TERM RECOVERY AT HOME (Months 1–18):

• Months 1–3: Continued neuromuscular retraining with a local physiotherapist (GAF provides referral network). EMG biofeedback sessions recommended 2–3 times per week.

• Months 3–6: First signs of muscle reinnervation expected for nerve graft/transfer cases (early twitching, increased muscle tone). For gracilis FFMT powered by CFNG, first signs of movement may not appear until 6–12 months post-operatively.

• Months 6–12: Progressive improvement in smile excursion, eye closure, and symmetry. Serial standardized photography and eFACE video analysis at 6 and 12 months.

• Month 12–18: Plateau of neurological recovery. Assessment for adjunctive procedures: botulinum toxin for synkinesis or contralateral hyperkinesis, brow lift, lower lid tightening, fat grafting for volume restoration.

• Stage 2 procedures (e.g., CFNG Stage 2 nerve coaptation to gracilis): Planned and coordinated by GAF Healthcare for a return visit if a staged protocol was used.